MedTrace Logo

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

NCT04812535 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-02-11

Study results available
· View outcomes & findings →

Summary

This is an open-label, "non comparative", non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms

Conditions

  • SCC - Squamous Cell Carcinoma of Skin

Interventions

DRUG

Vilobelimab

Vilobelimab Monotherapy

DRUG

Vilobelimab + pembrolizumab combination therapy

Vilobelimab + pembrolizumab combination therapy

Sponsors & Collaborators

Principal Investigators

  • Prof. Dr. D. Schadendorf, MD · University Hospital, Essen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2024-06-04
Completion
2024-06-04
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04812535 on ClinicalTrials.gov